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Background: The rate of peripheral arterial disease (PAD) progression among patients with type 2 diabetes (T2DM) and coronary artery disease 
(CAD) receiving aggressive medical therapy and according to glycemic treatment is unknown. 
Methods: We analyzed the incidence of PAD in 1,389 patients in the BARI 2D trial who had a normal ankle brachial index (ABI; 0.91-1.3) at 
baseline and ABI assessed beyond baseline. Incident PAD was defined as a new low ABI (≤0.9) during annual follow-up. Arterial stiffness was defined 
as a new non-compressible ankle artery.
Results: Newly manifest PAD was diagnosed in 6.9% of patients at year 1, 6.8% at year 2, and 5.4% at year 5. New arterial stiffness was identified 
in 3.4% of patients at year 1, 2.7% at year 2, and 3.9% at year 5. In patients randomized within BARI2D to the insulin sensitizing compared to 
insulin providing strategy, the rate of a new low ABI was significantly lower (p=0.0005) (Table), while the rate of new arterial stiffness was similar 
(p>0.5).
Conclusions: Despite aggressive medical therapy and risk modification, a significant proportion of patients with T2DM and CAD developed 
newly manifest PAD or non-compressible ankle arteries during follow-up, suggesting that high risk patients should be routinely screened for PAD. 
Additionally, in T2DM, an insulin sensitizing glycemic strategy may be associated with less progression of lower extremity vascular disease and is an 
area that deserves further study.
Annual Incidence of a NEW Low Ankle Brachial Index By Glycemic Strategy
Year
Insulin Providing Strategy Insulin Sensitizing Strategy
N % with NEW low ABI N % with NEW low ABI
1 662 6.8 673 7.0
2 585 8.7 603 5.0
3 527 5.5 554 3.4
4 425 6.6 465 3.4
5 235 7.2 281 3.9
6 122 4.9 132 1.5
P=0.0005
